Bioinformatics: Leveraging for Dollars
This article was originally published in Start Up
Executive SummarySelling research software is a tough way to generate big returns: there are dozens of competitors, most markets are small, and technology changes fast. Some companies are trying to create one-stop shopping solutions for large clients, building consulting and training businesses onto software sales in order to leverage up per-client fees. Others are creating one-stop-shops of a more democratic kind by exploiting the Web. Instead of selling to bioinformaticians, they're aggregating often easy-to-use versions of bioinformatics software and selling affordable subscriptions. But their real revenue generation model may be context-sensitive e-procurement: pointing out to customers which reagents to buy and then taking a percentage of the selling price.
You may also be interested in...
It is a world, at least the US corner of it, in which any common understanding of drug value is confused by opposing incentives – to opacity and transparency, to looking at benefit broadly or narrowly, long-term or short-term: value, in short, to whom?
Merck and UnitedHealth's Optum group have partnered to explore various value constructs.
Although stakeholders are interested in value-based models that link a drug’s performance to emerging evidence of improved patient outcomes, such agreements are difficult to implement and too limited in scope to drive a shift to value-based reimbursement. The authors suggest a new, structured approach to bring these contracts into the mainstream, thus transforming product reimbursement and fueling the shift from volume to value.